Company intelligence / Profile preview

Miravant Medical Technologies

Santa Barbara, California, United Statesradcliffecardiology.com ↗

Ownership: Private
Employees: ~47
Development stage: Other

Overview

Miravant’s lead product, PHOTREX (rostaporfin), completed two Phase III trials for wet AMD but failed to meet primary efficacy endpoints and did not receive FDA approval. Other pipeline programs were discontinued or remain inactive. The company’s proprietary PhotoPoint platform focused on light-responsive drugs combined with specialized devices for targeted tissue destruction in various indications including ophthalmology, dermatology, cardiovascular disease, and oncology.

Therapeutic areas: DermatologyOphthalmologyOncologyNephrologyCardiovascular
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Pharmacia Corp. licensed rostaporfin for development in several indications including ophthalmology and oncology

Beyond the preview

Go deeper on Miravant Medical Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miravant Medical Technologies.

Explore the full profile